A Phase Ib/II Study to Investigate the Safety , PK and PD of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
Latest Information Update: 07 Jul 2026
At a glance
- Drugs SHR 1819 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 02 Jul 2026 Actual Primary Completion date changed to 22 Nov 2025.
- 02 Jul 2026 Status changed from recruiting to completed.
- 10 Jul 2025 Planned End Date changed from 1 Aug 2025 to 1 Dec 2025.